Answer
Rifampicin, a potent CYP3A4 inducer, reduced mean exposure (AUC) to intravenously administered bortezomib by 45% in a study of 6 patients; concomitant use is not recommended because efficacy may be reduced.
Sources for this answer
- Velcade 3.5mg powder for solution for injection (Great Britain)Janssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.5 Interaction with other medicinal products · Version 37Document updated
Sources checked